Fibronectin 1 protein expression in clear cell renal cell carcinoma

Oncology Letters

Volumn 3, Issue 4, 2012, Pages 787-790

  Steffens, S ^a   Schrader, A J ^b   Vetter, Gesa ^a   Eggers, H ^a   Blasig, H ^a   Becker, J ^a   Kuczyk, M A ^a   Serth, J ^a  

^a HANNOVER MEDICAL SCHOOL   (Germany)

^b UNIVERSITY OF ULM MEDICAL SCHOOL   (Germany)

Author keywords

Fibronectin 1; Prognosis; Renal cell carcinoma

Indexed keywords

FIBRONECTIN 1; GLYCOPROTEIN; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; CALCULATION; CANCER MORTALITY; CANCER PROGNOSIS; CANCER STAGING; CANCER SURGERY; CANCER SURVIVAL; CANCER TISSUE; CONTROLLED STUDY; CYTOPLASM; FEMALE; FOLLOW UP; HUMAN; HUMAN TISSUE; KIDNEY CARCINOMA; KIDNEY TUMOR; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MALE; PROTEIN EXPRESSION; SURVIVAL TIME; TUMOR DIFFERENTIATION; VISCERAL METASTASIS;

EID: 84856888102     PISSN: 17921074     EISSN: 17921082     Source Type: Journal    
DOI: 10.3892/ol.2012.566     Document Type: Article

References (23)

1. Schrader AJ, Sevinc S, Olbert PJ, Hegele A, Varga Z and Hofmann R: Gender-specific characteristics and survival of renal cell carcinoma. Der Urologe 47: 1184-1186, 2008.
2. Tamaskar I, Choueiri TK, Sercia L, Rini B, Bukowski R and Zhou M: Differential expression of caveolin-1 in renal neoplasms. Cancer 110: 776-782, 2007.
3. Wilson CB, Leopard J, Cheresh DA and Nakamura RM: Extracellular matrix and integrin composition of the normal bladder wall. World J Urol 14: S30-S37, 1996.
4. Akiyama SK, Olden K and Yamada KM: Fibronectin and integrins in invasion and metastasis. Cancer Metastasis Rev 14: 173-189, 1995.
5. Warawdekar UM, Zingde SM, Iyer KS, Jagannath P, Mehta AR and Mehta NG: Elevated levels and fragmented nature of cellular fibronectin in the plasma of gastrointestinal and head and neck cancer patients. Clin Chim Acta 372: 83-93, 2006.
6. Waalkes S, Atschekzei F, Kramer MW, et al: Fibronectin 1 mRNA expression correlates with advanced disease in renal cancer. BMC Cancer 10: 503, 2010.
7. Fuhrman SA, Lasky LC and Limas C: Prognostic significance of morphologic parameters in renal cell carcinoma. Am J Surg Pathol 6: 655-663, 1982.
8. Stenzl A and De Kernion JB: Pathology, biology, and clinical staging of renal cell carcinoma. Semin Oncol 16 (Suppl 1): 3-11, 1989.
9. Theodorescu D, Broder SR, Boyd JC, Mills SE and Frierson HF Jr: Cathepsin D and chromogranin A as predictors of long term disease specific survival after radical prostatectomy for localized carcinoma of the prostate. Cancer 80: 2109-2119, 1997.
10. Merseburger AS, Hennenlotter J, Simon P, et al: Activation of the PKB/Akt pathway in histological benign prostatic tissue adjacent to the primary malignant lesions. Oncol Rep 16: 79-83, 2006.
11. Merseburger AS, Kramer MW, Hennenlotter J, et al: Involvement of decreased Galectin-3 expression in the pathogenesis and progression of prostate cancer. Prostate 68: 72-77, 2008.
12. Tezval H, Jurk S, Atschekzei F, Serth J, Kuczyk MA and Merseburger AS: The involvement of altered corticotropin releasing factor receptor 2 expression in prostate cancer due to alteration of anti-angiogenic signaling pathways. Prostate 69: 443-448, 2009.
13. Peters I, Rehmet K, Wilke N, et al: RASSF1A promoter methylation and expression analysis in normal and neoplastic kidney indicates a role in early tumorigenesis. Mol Cancer 6: 49, 2007.
14. De la Fuente MT, Casanova B, Garcia-Gila M, Silva A and Garcia-Pardo A: Fibronectin interaction with alpha4beta1 integrin prevents apoptosis in B cell chronic lymphocytic leukemia: correlation with Bcl-2 and Bax. Leukemia 13: 266-274, 1999.
15. Danen EH and Yamada KM: Fibronectin, integrins, and growth control. J Cell Physiol 189: 1-13, 2001.
16. Takayasu H, Horie H, Hiyama E, et al: Frequent deletions and mutations of the beta-catenin gene are associated with overexpression of cyclin D1 and fibronectin and poorly differentiated histology in childhood hepatoblastoma. Clin Cancer Res 7: 901-908, 2001.
17. Tapper J, Kettunen E, El-Rifai W, Seppala M, Andersson LC and Knuutila S: Changes in gene expression during progression of ovarian carcinoma. Cancer Genet Cytogenet 128: 1-6, 2001.
18. Murata J, Saiki I, Yoneda J and Azuma I: Differences in chemotaxis to fibronectin in weakly and highly metastatic tumor cells. Jpn J Cancer Res 83: 1327-1333, 1992.
19. Lohi J, Tani T, Leivo I, et al: Expression of laminin in renal-cell carcinomas, renal-cell carcinoma cell lines and xenografts in nude mice. Int J Cancer 68: 364-371, 1996.
20. Brenner W, Gross S, Steinbach F, Horn S, Hohenfellner R and Thuroff JW: Differential inhibition of renal cancer cell invasion mediated by fibronectin, collagen IV and laminin. Cancer Lett 155: 199-205, 2000.
21. Wunderlich H, Wilhelm S, Reichelt O, Zermann DH, Borner R and Schubert J: Renal cell carcinoma in renal graft recipients and donors: incidence and consequence. Urol Int 67: 24-27, 2001.
22. Hegele A, Heidenreich A, Varga Z, et al: Cellular fibronectin in patients with transitional cell carcinoma of the bladder. Urol Res 30: 363-366, 2003.
23. He Z, Liu S, Guo M, Mao J and Hughson MD: Expression of fibronectin and HIF-1alpha in renal cell carcinomas: relationship to von Hippel-Lindau gene inactivation. Cancer Genet Cytogenet 152: 89-94, 2004.